Biotech’s TROP2 antibody drug conjugate sac-TMT for marketing in second indication: Chengdu, China Wednesday, March 12, 2025, 11:00 Hrs [IST] Sichuan K ...

Taxane chemotherapy is unable to sensitize prostate cancer to immune checkpoint inhibitors, resulting in another negative trial with immunotherapy in prostate cancer,” said Andrea Necchi, MD.

(the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) was approved ...

This perioperative approach with Imfinzi underscores our commitment to moving into earlier stages of cancer where novel ...

Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...

AstraZeneca's Imfinzi perioperative regimen improved event-free survival in gastric and GEJ cancer. The trial showed a strong ...

of 8.8 months (95% confidence interval (CI), 8.5 – not estimable (NE)), while the median overall survival (OS) was not estimable (95% CI, NE – NE), and patients with PDAC harboring any RAS ...

PLEASE NOTE: Flashing software like Lineage OS on a device is an “at your own risk” activity. Even if you follow our guide to the letter, we can’t accept any responsibility if your device ...

Many users noticed the Dell SupportAssist OS Recovery tool on their PC, and they don’t know what it does. In today’s guide, we’re going to take a closer look at this tool and show you everything you ...

Continuously evolving and upgrading: Regular software updates to ensure the TV OS stays compatible with new apps, content formats, and evolving securities & technologies. Televisions powered by ...